Scuttlebutt
Subscribe
Sign in
Home
Notes
Chat
📰 Editions
🧭 Topics
🎙️ Sources
🗣️ People
📈 Investments
💡 Themes
Archive
About
GLP-1 drugs
Latest
Top
Discussions
Strive Pharmacy CEO on the GLP-1 boom: "we've grown to over 1,100 employees"
11 lessons: why Strive never took outside money, potency tests run several times a week instead of once a year, and how far big pharma's lobbyists…
11 hrs ago
•
Scuttlebutt
Ro grew from a $250M to a $3B+ run rate with fewer staff than in 2021, says its CEO
9 lessons: why PBMs are "the appendix of the healthcare system," how Ro cut 20% of staff and then grew 100% a year, and why AI turns a specialist into a…
Nov 12
•
Scuttlebutt
Alphabet had its worst day since 2004 as search growth slowed to 12% — Equity Mates
15 moments: a leaked memo that has one host ready to sell Sea Limited, why Eli Lilly is now a GLP-1 stock, and the 5% sizing rule from David Gardner's…
Nov 9
•
Scuttlebutt
Acquirer's Fund founder on Deckers: "At $77, this is being priced as if it has no growth"
8 calls: why Novo Nordisk at 12 times forward earnings is priced for no new drugs, why S&P Global fell below $400 on AI fears, and a $72 to $160 range…
Nov 1
•
Scuttlebutt
"Now we're extending that into a 4-hour peak": Starbucks CEO on the morning rush
4 moments: why Brian says Q4 came from running the basics well, how pastries are riding along with drinks, the afternoon plan, and his answer on GLP-1…
Oct 31
•
Scuttlebutt
Wine and liquor fell from 33% to 24% of sales in 18 months — Chicago's North Pond owner
9 lessons: why obeying labor law costs 5–10% against rivals, how a $130 menu leans on $110 bottles, and why $400 dinners are now for milestones
Oct 25
•
Scuttlebutt
About 1 in 10 Kroger shoppers are affected by GLP-1s, moving carts to protein, CEO finds
7 takeaways: how a $5 billion price-cut plan gets paid for, why e-commerce at 10-15% of food sales could reach 25-30%, and the single-person households…
Oct 22
•
Scuttlebutt
Hershey CEO on GLP-1s: "over 30% of our portfolio is in portion control"
9 takeaways: why cocoa prices spiked, how an AI tool tells the CEO which store to visit next, and why Hershey's century-old trust keeps activists out
Sep 30
•
Scuttlebutt
Canada should give weight-loss drugs away for free, says Harris Douglas portfolio manager
18 calls: why price-sensitive buyers now set the 10-year Treasury, the one stock he says he totally missed, and new picks in Meta, Microsoft and…
Sep 29
•
Scuttlebutt
"It's actually quantum computing": Blue Whale's CIO on the biggest risk to Nvidia
14 arguments: why Nvidia at 16 to 17 times earnings is an earnings bubble, not a valuation one, why he owns Newmont instead of gold, and why Taiwan is…
Sep 29
•
Scuttlebutt
Plexo Capital founder: the best new fund managers are far more technical than 10 yrs ago
9 lessons: why small venture funds can no longer hold their stakes, how Plexo's first SPV bought into Anthropic at $18B, and why some managers now hunt…
Sep 29
•
Scuttlebutt
80% market share for Novo's weight-loss pill despite a rival, Novo Nordisk's CEO finds
11 takeaways: Why Novo wants 10 times more patients on its pill by decade's end, where he would buy drugs from outside, and why he worries Europe's best…
Sep 25
•
Scuttlebutt
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts